Keros Therapeutics Q1 2026 Earnings Report

Keros Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.02
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Keros Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.93 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Keros Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 5/11/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Keros Therapeutics (NASDAQ:KROS) (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis. KER-050 is currently being evaluated in multiple clinical trials across North America and Europe. In parallel, Keros is advancing additional preclinical programs that leverage its proprietary platform to address other hematologic and iron-related disorders.

Founded in 2019 as a spin-out from academic research, Keros Therapeutics is headquartered in Boston, Massachusetts, and collaborates with leading research institutions and clinical centers worldwide. The company’s leadership team comprises industry veterans in research and development, clinical operations and regulatory affairs, all focused on translating groundbreaking science into therapies that improve patient outcomes in serious blood diseases.